课题基金 / 基金详情

Parkinson Disease Neuroprotection Clinical Trial

Parkinson Disease Neuroprotection Clinical Trial
帕金森病神经保护临床试验
批准号:
6663137
负责人:
ROBERT W HAMILL
金额:
$6.19万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-30 至 2007-11-30

项目摘要

项目成果

ROBERT W HAMILL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The NINDS seeks to establish Clinical Trial Sites that will collaborate and cooperate in the development and testing of new approaches to neuroprotection therapy. The Neurology programs at the University of Vermont College of Medicine (UVM/COM), the Dartmouth Hitchcock Medical Center (DHMC), and Maine Neurology (Maine Medical Center) will work together in order to establish a Northern New England Clinical Trials Center (NNE-CTC). Specifically, the aims of the NNE-CTC are:To recruit and follow subjects with early Parkinson's disease (PD) for a randomized clinical trial of Neuroprotection in PD;To provide high quality clinical assessment, and data entry and management, and to meet all regulatory statutes outlined for experimental neurotherapeutics;To evolve new approaches to interventional therapy and assessment strategies as permitted within the structure of the Center and overall project;To fully integrate our Clinical Center into the operation of the NINDS sponsored Neuroprotection Trial program and to fully cooperate with all aspects of the trial.In addition to these specific aims, an overall goal of the NNE-CTC is to bring opportunities for the citizens of Northern New England and Upstate New York to participate in the evolving therapies for neurodegenerative disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: CREATINE IN SUBJECTS WITH TREATED PARKINSON'S DISEASE (PD)
CLINICAL TRIAL: CREATINE IN SUBJECTS WITH TREATED PARKINSON'S DISEASE (PD)
DNA REPOSITORY FOR PATIENTS WITH PARKINSON'S DISEASE
MINOCYCLINE AMP; CREATINE IN EARLY UNTREATED PARKINSON'S DISEASE
海外基金